CONTINUED EFFICACY AND SAFETY THROUGH 4 YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102): PRELIMINARY ANALYSIS

被引：0

作者：

Marcellin, Patrick ^{[2
]}

Buti, Maria ^{[3
]}

Krastev, Zahary ^{[4
]}

Gurel, Selim ^{[5
]}

Di Bisceglie, Adrian M. ^{[6
]}

Odin, Joseph A. ^{[7
]}

Dusheiko, Geoffrey M. ^{[8
]}

Heathcote, E. Jenny ^{[9
]}

Borroto-Esoda, Katyna ^{[1
]}

Coombs, Derek H. ^{[1
]}

Mondou, Elsa ^{[1
]}

Anderson, Jane ^{[1
]}

机构：

[1] Gilead Sci, Durham, NC USA

[2] Univ Paris, Hop Beaujon, Clichy, France

[3] Univ Vall Hebron & Ciberehd, Serv Med Interna Hepatol, Gen Hosp, Barcelona, Spain

[4] Univ Hosp St Ivan Rilsky, Sofia, Bulgaria

[5] Uludag Univ, Bursa, Turkey

[6] St Louis Univ, Sch Med, St Louis, MO USA

[7] Mt Sinai Sch Med, New York, NY USA

[8] Royal Free Hosp, London NW3 2QG, England

[9] Univ Toronto, Toronto, ON, Canada

来源：

HEPATOLOGY | 2010年 / 52卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

476

引用

页码：555A / 556A

页数：2

共 50 条

[1] THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102); PRELIMINARY ANALYSIS
Marcellin, Patrick
Buti, Maria
Krastev, Zahary
Germanidis, George
Kaita, Kelly D.
Kotzev, Iskren
Buggisch, Peter
Weilert, Frank
Trinh, Huy N.
Gurel, Selim
Heathcote, E. Jenny
Sorbel, Jeff
Anderson, Jane
Mondou, Elsa
Rousseau, Franck
HEPATOLOGY, 2009, 50 (04) : 532A - 533A
[2] THREE YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B, PRELIMINARY ANALYSIS
Lee, Samuel S.
Heathcote, E. Jenny
Sievert, William
Trinh, Huy N.
Kaita, Kelly D.
Younossi, Zobair M.
George, Jacob
Shiffman, Mitchell L.
Marcellin, Patrick
Sorbel, Jeff
Anderson, Jane
Mondou, Elsa
Ouinn, Joe
Rousseau, Franck
HEPATOLOGY, 2009, 50 (04) : 538A - 538A
[3] THREE YEARS OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-NEGATIVE AND POSITIVE PATIENTS WITH CHRONIC HEPATITIS B (STUDY 102 AND STUDY 103)
Rizzetto, M.
Marcellin, P.
Heathcote, E. J.
Sorbel, J.
Mondou, E.
Anderson, J.
Rousseau, F.
DIGESTIVE AND LIVER DISEASE, 2010, 42 : S8 - S9
[4] FOUR YEARS EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) IN ASIANS WITH HBEAG-POSITIVE AND HBEAG-NEGATIVE CHRONIC HEPATITIS B (CHB), PRELIMINARY ANALYSIS
Gane, Edward J.
Lee, Samuel S.
Heathcote, E. Jenny
Sievert, William
Trinh, Huy N.
Kaita, Kelly D.
Younossi, Zobair M.
George, Jacob
Marcellin, Patrick
Coombs, Derek H.
Anderson, Jane
Mondou, Elsa
HEPATOLOGY, 2010, 52 (04) : 559A - 559A
[5] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B
Chan, Henry Lik Yuen
Lim, Young-Suk
Seto, Wai Kay Walter
Agarwal, Kosh
Brunetto, Maurizia R.
Janssen, Harry L. A.
Caruntu, Florin
Stepanova, Tatjana
Tsang, Owen
Yatsuhashi, Hiroshi
Tak, Won Young
Chen, Chi-Yi
Celen, Mustafa
Suri, Vithika
Flaherty, John F.
Lin, Lanjia
Cathcart, Andrea
Gaggar, Anuj
Pan, Calvin Q.
Shalimar
Buti, Maria
HEPATOLOGY, 2018, 68 : 227A - 228A
[6] Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: Week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102)
Marcellin, P.
Jacobson, I.
Habersetzer, F.
Senturk, H.
Andreone, P.
Moyes, C.
Horban, A.
Teuber, G.
Sorbel, J.
Anderson, J.
Mondou, E.
Quinn, J.
Rousseau, F.
JOURNAL OF HEPATOLOGY, 2008, 48 : S26 - S26
[7] LONG TERM (4 YEAR) EFFICACY AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE (TDF) TREATMENT IN HBEAG-POSITIVE PATIENTS (HBEAG plus ) WITH CHRONIC HEPATITIS B (STUDY 103): PRELIMINARY ANALYSIS
Heathcote, E. Jenny
Gane, Edward J.
deMan, Robert A.
Chan, Sing
George, Jacob
Tsai, Naoky C. S. C.
Marcellin, Patrick
Snow-Lampart, Andrea
Coombs, Derek H.
Mondou, Elsa
Anderson, Jane
HEPATOLOGY, 2010, 52 (04) : 556A - 557A
[8] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy and safety results
Cheng, W.
Pianko, S.
Thompson, A.
Buti, M.
Gane, E.
Seto, W. K.
Chan, H. L. Y.
Chuang, W-L
Stepanova, T.
Hui, A-J
Lim, Y-S
Mehta, R.
Janssen, H.
Acharya, S. K.
Flaherty, J. F.
Massetto, B.
Cathcart, A.
Dinh, P.
Subramanian, G. M.
Mchutchison, J. G.
Pan, C.
Brunetto, M.
Izumi, N.
Marcellin, P.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 68 - 69
[9] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-NEGATIVE, CHRONIC HEPATITIS B PATIENTS: A GLOBAL PHASE 3 STUDY
Brunetto, Maurizia Rossana
Lim, Young-Suk
Gane, Edward
Seto, Wai-Kay
Osipenko, Marina
Ahn, Sang Hoon
Janssen, Harry L.
Shukla, Akash
Chuang, Wan-Long
Trinh, Huy N.
Celen, Mustafa
Flaherty, John F.
Chan, Alain
Lau, Audrey
Gaggar, Anuj
Suri, Vithika
Subramanian, Mani
Pan, Calvin Q.
Izumi, Namiki
Marcellin, Patrick
Chan, Henry L.
Buti, Maria
GASTROENTEROLOGY, 2017, 152 (05) : S1086 - S1086
[10] A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96
Brunetto, M.
Lim, Y. S.
Gane, E.
Seto, W. K.
Osipenko, M.
Ahn, S. H.
Janssen, H. L.
Shukla, A.
Chuang, W. L.
Trinh, H.
Celen, M. K.
Flaherty, J. F.
Lau, A. H.
Gaggar, A.
Suri, V.
Bhardwaj, N.
Kim, K.
Subramanian, G. M.
Pan, C.
Izumi, N.
Marcellin, P.
Chan, H.
Buti, M.
JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S25 - S26

← 1 2 3 4 5 →